(VIANEWS) –
About AFFLUENT MEDICAL
Affluent Medical SA, established in Aix-en-Provence, France in 2011, specializes in minimally invasive technologies for treating heart and vascular diseases. Their product portfolio includes Kardiozis for abdominal aortic aneurysm treatment; Kalios and Epygon mitral insufficiency treatments; Artus implant for severe urinary incontinence treatment in both men and women; with innovation as their cornerstone, Affluent Medical SA strives to improve patient outcomes with their technologies.
Yearly Analysis
Based on available information, AFFLUENT MEDICAL is currently trading at EUR1.62, below its 52-week high of EUR2.30 but above its 52-week low of EUR0.93. This indicates a significant price movement over the last year.
To form an investment outlook, it is crucial to take into account various aspects of AFFLUENT MEDICAL’s financial performance, industry trends and overall market conditions. Unfortunately, due to this being an abbreviated analysis it can be challenging to provide an in-depth evaluation.
Before making any investment decisions, investors should conduct extensive research and analysis, taking into account their investment objectives, risk tolerance and any other personal factors. They may also consult a financial professional for tailored advice.
Technical Analysis
AFFLUENT MEDICAL’s stock has experienced an extraordinary upsurge in value over recent weeks and months, as evidenced by its current price being considerably above both its 50-day and 200-day moving averages of EUR1.31 and EUR1.23, respectively. This indicates a strong upward trend in its price.
Trading volume for AFFLUENT MEDICAL has also seen a marked increase, exceeding its average daily volume by 314.45% and reaching 36845 today – an indication of increased investor participation that may contribute to further price gains.
As far as volatility goes, AFFLUENT MEDICAL has experienced relatively low intraday fluctuations over the last quarter with an average intraday variation of 3.83% on average; however, its highest amplitude of average volatility reached 4.76% last week which indicates more potential fluctuations for AFFLUENT MEDICAL in its near future.
According to the stochastic oscillator, an indicator commonly used to gauge overbought and oversold conditions, AFFLUENT MEDICAL’s stock is currently considered oversold (=20). This indicates that its prices could potentially experience a correction or rebound and offer investors an opportunity to purchase the shares at lower prices.
Overall, AFFLUENT MEDICAL’s current stock price and trading activity suggests an optimistic upward trend; however, investors should remain wary of potential volatility as well as any price correction in the near future.
Quarter Analysis
This section offers a concise analysis of the company’s revenue growth over the past year. According to our data, year-on-year quarterly revenue growth has declined by 16.3% resulting in total of 1.22M for twelve trailing months. Investors can use this information to assess its financial performance and potential growth.
Equity Analysis
According to financial data provided, AFFLUENT MEDICAL has reported trailing twelve month earnings per share (EPS) of EUR-0.65, signifying negative earnings during that timeframe and suggesting it may not be producing enough profits to sustain operations or deliver returns to investors.
Return on Equity (ROE) of the company over its most recent twelve-month period is negative -40.37%, meaning for every EUR1 of shareholder’s equity it generated a loss of EUR0.4037. A negative ROE could signal that its assets aren’t being effectively utilized to generate profits for shareholders.
Investors should carefully consider these financial metrics prior to making investment decisions. Conduct additional research and analysis in order to ascertain if the company’s financial performance will improve over time, which would produce positive returns for investors. In addition, investors should take into account other aspects such as its competitive standing, growth prospects and overall market conditions before making any definitive investment decisions.
More news about AFFLUENT MEDICAL (AFME.PA).
